Acutaas Chemicals (ACUTAAS) Q4 24/25 earnings summary

Executive summary

• Revenue for FY25 surpassed ₹10,069 million (INR 1,006.9 crore), reflecting 40.3% YoY growth and a strategic rebranding to Acutaas Chemicals Limited.

• EBITDA grew 80.6% YoY to ₹2,321 million, and PAT nearly doubled to ₹1,604 million, up 98.6% YoY.

• Audited standalone and consolidated financial results for FY25 were approved with an unmodified auditor opinion.

• Management targets 25% revenue growth in FY26, continuing robust performance across all business segments.

• The company is positioned to benefit from global supply chain shifts, especially as India emerges as an alternative to China in specialty chemicals and pharmaceuticals.

Financial highlights

• Q4 FY25 revenue reached ₹3,085 million, up 37.1% YoY; gross margin expanded to 47.3%.

• Q4 FY25 EBITDA was ₹850 million, up 96.8% YoY; PAT for Q4 was ₹627 million, up 144.2% YoY.

• FY25 consolidated revenue was ₹100,687.55 lakh, with net profit at ₹16,041.77 lakh.

• Exports contributed 74% of Q4 FY25 revenue.

• Net cash and cash equivalents at ₹18,522.43 lakh (consolidated) as of March 31, 2025.

Outlook and guidance

• Management anticipates 25% revenue growth in FY26, a rate consistently achieved for 15 years.

• CDMO business expected to grow with new contracts and late-stage molecules moving to commercialization.

• Electrolyte additive business to commence production in H2 FY26, with gradual ramp-up over three years.

• Margins expected to improve further in FY26, with seasonality leading to lower margins in H1 and stronger H2 performance.

• Focus on expanding innovator business and commercializing products ahead of patent expiry.